Suppressors of cytokine signalling (SOCS) in the immune system

Nature Reviews Immunology

Volumn 2, Issue 6, 2002, Pages 410-416

  Alexander, Warren S ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERFERON; PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATOR PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; BIOLOGICAL MODEL; FEEDBACK SYSTEM; GENETICS; HUMAN; IMMUNOLOGY; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL CELL; ANTIGEN EXPRESSION; GENE OVEREXPRESSION; IMMUNE SYSTEM; KNOCKOUT MOUSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

ANIMALS; CYTOKINES; FEEDBACK; HUMANS; INTERFERONS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; PROTEINS; SIGNAL TRANSDUCTION;

EID: 0036595049     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri818     Document Type: Review

References (92)

1. Nicola, N. A. (ed.) Guidebook to Cytokines and Their Receptors (Oxford University Press, Oxford, 1994).
2. Gearing, D. P., King, J. A., Gough, N. M. & Nicola, N. A. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J. 8, 3667-3676 (1989).
3. Ihle, J. N. Cytokine receptor signalling. Nature 377, 591-594 (1995).
4. Ivashkiv, L. B. Jak-STAT signaling pathways in cells of the immune system. Rev. Immunogenet. 2, 220-230 (2000)
5. Duhe, R. J., Wang, L. H. & Farrar, W. L. Negative regulation of Janus kinases. Cell. Biochem. Biophys. 34, 17-59 (2001)
6. Starr, R. & Hilton, D. Negative regulation of the JAK/STAT pathway. Bioessays 21, 47-52 (1999).
7. Hilton, D. J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl Acad. Sci. USA 95, 114-119 (1998). This paper describes the extended SOCS family of proteins, which are characterized by a carboxy-terminal SOCS-box motif.
8. Naka, T. et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929 (1997).
9. Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921 (1997).
10. Endo, T. A. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924 (1997).
11. Matsumoto, A. et al. Suppression of STAT5 functions in liver, mammary glands and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 19, 6396-6407 (1999).
12. Yasukawa, H. et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320 (1999).
13. Nicholson, S. E. et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18, 375-385 (1999). References 12 and 13 describe the SH2- and amino-terminal-domain requirements for the interaction of SOCS1 with JAKs and the inhibition of kinase activity.
14. Sasaki, A. et al. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275, 29338-29347 (2000).
15. Nicholson, S. E. et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97, 6493-6498 (2000).
16. Hansen, J. A., Lindberg, K., Hilton, D. J., Nielsen, J. H. & Billestrup, N. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13, 1832-1843 (1999).
17. Bjorbaek, C. et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275, 40649-40657 (2000).
18. Cohney, S. J. et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell. Biol. 19, 4980-4988 (1999).
19. Sasaki, A. et al. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275, 29338-29347 (2000).
20. Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C. & Schaper, F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275, 12848-12856 (2000).
21. Kamura, T. et al. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat and ankyrin repeat families. Genes Dev. 12, 3872-3881 (1998).
22. Zhang, J. G. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl Acad. Sci. USA 96, 2071-2076 (1999). References 21 and 22 show that the SOCS-box domain binds elongins B and C, which establishes a link to the proteasomal degradation pathway.
23. Yu, C. L. & Burakoff, S. J. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272, 14017-14020 (1997).
24. Verdier, F. et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein J. Biol. Chem. 273, 28185-28190 (1998).
25. De Sepulveda, P., Ilangumaran, S. & Rottapel, R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275, 14005-14008 (2000).
26. Kamizono, S. et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276, 12530-12538 (2001).
27. Frantsve, J., Schwaller, J., Sternberg, D. W., Kutok, J. & Gilliland, D. G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 21, 3547-3557 (2001).
28. Zhang, J. G. et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl Acad. Sci. USA 98, 13261-13265 (2001).
29. Krebs, D. L. & Hilton, D. J. SOCS: physiological suppressors of cytokine signaling. J. Cell. Sci. 113, 2813-2819 (2000).
30. Greenhalgh, C. J. & Hilton, D. J. Negative regulation of cytokine signaling. J. Leukocyte Biol. 70, 348-356 (2001).
31. Fujimoto, M. et al. Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice. J. Immunol. 165, 1799-1806 (2000).
32. Marine, J. C. et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98, 609-616 (1999)
33. Naka, T. et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1)-deficient mice. Proc. Natl Acad. Sci. USA 95, 15577-15582 (1998).
34. -/- mice.
35. Gresser, I. et al. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am. J. Pathol. 102, 396-402 (1981).
36. -/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease. Immunology 104, 92-98 (2001).
37. Alexander, W. S. et al. SOCS1 is a critical inhibitor of interferon-γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 (1999).
38. Brysha, M. et al. Suppressor of cytokine signaling-1 attenuates the duration of interferon-γ signal transduction in vitro and in vivo. J. Biol. Chem. 276, 22086-22089 (2001).
39. Naka, T. et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity 14, 535-545 (2001).
40. Metcalf, D., Di Rago, L., Mifsud, S., Hartley, L. & Alexander, W. S. The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-γ and lacking the SOCS-1 gene. Proc. Natl Acad. Sci. USA 97, 9174-9179 (2000).
41. Metcalf, D, et al. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl Acad. Sci. USA 99, 943-948 (2002)
42. H1 differentiation by IL-6 is mediated by SOCS1. Immunity 13, 805-815 (2000).
43. Morita, Y. et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor-necrosis-factor-α-induced cell death in fibroblasts. Proc. Natl Acad. Sci. USA 97, 5405-5410 (2000).
44. Matsuda, T., Yamamoto, T., Kishi, H., Yoshimura, A. & Muraguchi, A. SOCS-1 can suppress CD3ζ- and Syk-mediated NF-AT activation in a non-lymphoid cell line. FEBS Lett. 472, 235-240 (2000).
45. Li, S. et al. Cytokine-induced Src-homology 2 protein (CIS) promotes T-cell receptor-mediated proliferation and prolongs survival of activated T cells. J. Exp. Med. 191, 985-994 (2000).
46. Marine, J. C. et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98, 617-627 (1999).
47. Metcalf, D. et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405, 1069-1073 (2000).
48. Roberts, A. W. et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl Acad. Sci. USA 98, 9324-9329 (2001).
49. Gouilleux-Gruart, V. et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87, 1692-1697 (1996).
50. Frank, D. A., Mahajan, S. & Ritz, J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 100, 3140-3148 (1997).
51. Chai, S. K., Nichols, G. L. & Rothman, P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159, 4720-4728 (1997).
52. Suzuki, A. et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193, 471-481 (2001).
53. Shouda, T. et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108, 1781-1788 (2001). This study indicated the efficacy of Socs3 gene therapy for the treatment of experimental arthritis in mice.
54. Dalpke, A. H., Opper S., Zimmermann, S. & Heeg, K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166, 7082-7089 (2001).
55. Stoiber, D. et al. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-γ. J. Immunol. 163, 2640-2647 (1999).
56. Aman, M. J. et al. CIS associates with the interlukin-2 receptor β-chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. 274, 30266-30272 (1999).
57. Yoshimura, A. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin-3 and erythropoietin receptors. EMBO J. 14, 2816-2826 (1995).
58. Lejeune, D., Demoulin, J. B. & Renauld, J. C. Interleukin-9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin-9 signalling. Biochem. J. 353, 109-116 (2001).
59. Shen, X., Hong, F., Nguyen, V. A. & Gao, B. IL-10 attenuates IFN-α-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 480, 132-136 (2000).
60. Adams, T. E. et al. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273, 1285-1287 (1998).
61. Pezet, A., Favre, H., Kelly, P. A. & Edery, M. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J. Biol. Chem. 274, 24497-24502 (1999).
62. Isaksen, D. E. et al. Requirement for Stat5 in thymic stromal lymphopoietin-mediated signal transduction. J. Immunol. 163, 5971-5977 (1999).
63. Sadowski, C. L. et al. Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5*. J. Biol. Chem. 276, 20703-20710 (2001).
64. Bjorbaek, C. et al. Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Endocrinology 140, 2035-2043 (1999).
65. Emilsson, V., Arch, J. R., de Groot, R. P., Lister, C. A. & Cawthorne, M. A. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 455, 170-174 (1999)
66. Okabe, S. et al. Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway. Exp. Hematol. 27, 1542-1547 (1999).
67. Ram, P. A. & Waxman, D. J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem 274, 35553-35561 (1999).
68. Zong, C. S. et al. Mechanism of STAT3 activation by insulin-like growth factor 1 receptor. J. Biol. Chem. 275, 15099-15105 (2000).
69. Spom, B., Kovanen, P. E., Sasaki, A., Yoshimura, A. & Leonard, W. J. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling Blood 97, 221-226 (2001).
70. Park, E. S. et al. Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol. Endocrinol. 14, 440-448 (2000).
71. De Sepulveda, P. et al. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 18, 904-915 (1999).
72. Hamanaka, I. et al. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo. Circ. Res. 88, 727-732 (2001).
73. Wang, Q., Miyakawa, Y., Fox, N. & Kaushansky, K. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96, 2093-2099 (2000).
74. Sakamoto, H. et al. A Janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons. Blood 92, 1668-1676 (1998).
75. Losman, J. A., Chen, X. P., Hilton, D. & Rothman, P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J. Immunol. 162, 3770-3774 (1999).
76. Trop, S., De Sepulveda, P., Zuniga-Pflucker, J. C. & Rottapel, R. Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood 97, 2269-2277 (2001).
77. Bourette, R. P. et al. Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signal. J. Biol. Chem. 276, 22133-22139 (2001).
78. Kawazoe, Y. et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193, 263-269 (2001).
79. Song, M. M. & Shuai, K. The suppressor of cytokine signaling (SOCS)1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 273, 35056-35062 (1998).
80. Minamoto, S. et al. Cloning and functional analysis of new members of STAT-induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun. 237, 79-83 (1997).
81. Boisclair Y. R., Wang, J., Shi, J., Hurst, K. R. & Ooi, G. T. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1β on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J. Biol. Chem. 275, 3841-3847 (2000).
82. Magrangeas, F., Boisteau, O., Denis S., Jacques, Y. & Minvielle, S. Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem. J. 353, 223-230 (2001).
83. Auernhammer, C. J. & Melmed, S. Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology 140, 1550-1566 (1999).
84. Kotenko, S. V. et al. Identification, cloning and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J. Immunol. 166, 7096-7103 (2001).
85. Cacalano, N. A., Sanden, D. & Johnston, J. A. Tyrosine-phosphorated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nature Cell. Biol. 3, 460-465 (2001).
86. Terstegen, L. et al. The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J. Biol. Chem. 275, 18810-18817 (2000).
87. Auernhammer, C. J., Chesnokova, V., Bousquet, C. & Melmed, S. Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol. Endocrinol. 12, 954-961 (1998).
88. Magrangeas, F., Boisteau, O., Denis, S., Jacques, Y. & Minvielle, S. Negative regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3). Eur. Cytokine Netw. 12, 309-315 (2001).
89. Bjorbaek, C., Elmquist, J. K., Frantz, J. D., Shoelson, S. E. & Flier, J. S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell. 1, 619-625 (1998).
90. Hong, F., Nguyen, V. A. & Gao, B. Tumor-necrosis factor-α attenuates interferon-α signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J. 15, 1595-1597 (2001).
91. Karlsen, A. E. et al. Suppressor of cytokine signaling 3 (SOCS-3) protects β-cells against interleukin-1β- and interferon-γ -mediated toxicity. Proc. Natl Acad. Sci. USA 98, 12191-12196 (2001).
92. Emanuelli, B. et al. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275, 15985-15991 (2000).